----item----
version: 1
id: {1224AFEA-7C9A-4F68-9CF0-5211493DDE94}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/11/08/Seattle Genetics Wins 3rd Indication For Adcetris
parent: {DB30F1A8-28AC-4826-9401-DF423A977628}
name: Seattle Genetics Wins 3rd Indication For Adcetris
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: fe91fbdf-63a5-4253-8738-6c748ff2fe15

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 155

{3B33748A-17E9-4241-8447-989BB3484DFB}|{07CF1C44-428A-445B-98D8-5EA9905BD7C5}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{6DDF7877-FDAE-472B-8739-FB4710DF7651}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 49

Seattle Genetics Wins 3rd Indication For Adcetris
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 49

Seattle Genetics Wins 3rd Indication For Adcetris
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1388

<p>Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval &ndash; classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.</p><p>The approval was based on data from Seattle Genetics' Phase III AETHERA study.</p><p>The FDA also converted Adcetris' accelerated approval of the drug in the relapsed classical HL indication, which Seattle Genetics <a href="http://www.scripintelligence.com/home/Early-Adcetris-OK-no-surprise-to-SGEN-after-taking-US-FDAs-advice-320240" target="_new">won in 2011</a>, to a regular approval based on data from the trial.</p><p>Adcetris also was previously approved to treat systemic anaplastic large cell lymphoma, a rare T-cell non-Hodgkin's lymphoma with tumor cells that express CD30. </p><p>The AETHERA study was designed to compare up to 16 cycles of Adcetris, or one year of treatment, every three weeks following auto-HSCT, versus placebo. </p><p>The primary endpoint was met with a significant improvement in median progression-free survival of 42.9 months in the Adcetris group compared with 24.1 months in the placebo arm</p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 425

<p>Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval &ndash; classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 49

Seattle Genetics Wins 3rd Indication For Adcetris
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151108T064820
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151108T064820
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151108T064820
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029532
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 49

Seattle Genetics Wins 3rd Indication For Adcetris
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359906
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042436Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

fe91fbdf-63a5-4253-8738-6c748ff2fe15
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042436Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
